Effects of Rifampin on Tacrolimus Pharmacokinetics in Healthy Volunteers

Hébert, Mary F.; Fisher, Russell S.; Marsh, Christopher L.; Dressler, Dawna; Bekersky, Ihor

doi:10.1177/00912709922007499

Cited by 129 publications

(72 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The variation in morbidity of anti-tuberculosis therapy depends in part on the immunosuppressive regimens. Patients on cyclosporine A (CsA) (23,(25)(26)(27) and tacrolimus (28,29) seem to be at higher risk of graft loss when these medications are combined with an antituberculosis drug such as rifampin. This is in part due to the cytochrome P450 induction of the metabolism of CsA by rifampin and the need for increased dosing of CsA.…”

Section: Discussionmentioning

confidence: 99%

Mycobacterium Tuberculosis Infection Incidence in Hospitalized Renal Transplant Patients in the United States, 1998–2000

Klote¹,

Agodoa²,

Abbott³

2004

American Journal of Transplantation

View full text Add to dashboard Cite

The incidence, risk factors, and prognosis for Mycobacterium tuberculosis (MTB) infection have not been reported in a national population of renal transplant recipients. We performed a retrospective cohort study of 15 870 Medicare patients who received renal transplants from January 1 1998 to July 31 2000. Cox regression analysis derived adjusted hazard ratios (AHR) for factors associated with a diagnosis of MTB infection (by Medicare Institutional Claims) and the association of MTB infection with survival. There were 66 renal transplant recipients diagnosed with tuberculosis infection after transplant (2.5 cases per 1000 person years at risk, with some falling off of cases over time). The most common diagnosis was pulmonary TB (41 cases). In Cox regression analysis, only systemic lupus erythematosus (SLE) was independently associated with TB. Mortality after TB was diagnosed was 23% at 1 year, which was significantly higher than in renal transplant recipients without TB (AHR, 4.13, 95% CI, 2.21, 7.71, p < 0.001). Although uncommon, MTB infection is associated with a substantially increased risk of mortality after renal transplantation. High-risk groups, particularly those with SLE prior to transplant, might benefit from intensified screening.

show abstract

Section: Discussionmentioning

confidence: 99%

Mycobacterium Tuberculosis Infection Incidence in Hospitalized Renal Transplant Patients in the United States, 1998–2000

Klote¹,

Agodoa²,

Abbott³

2004

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…Other examples for which individual estimates of F G were available in the literature include tacrolimus (Floren et al, 1997;Hebert et al, 1999) and terfenadine (Clifford et al, 1997). The interindividual variabilities of in vivo F G estimates for tacrolimus and terfenadine were 36 and 54%, respectively.…”

Section: F G Predictions Using Individual Jejunal Microsomal Samplesmentioning

confidence: 99%

Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal Extraction

Gertz

Houston²,

Galetin³

2011

Drug Metab Dispos

115

View full text Add to dashboard Cite

show abstract

“…4 Hebert et al 40 evaluated the pharmacokinetics of tacrolimus in 6 healthy volunteers. Subjects were treated with either a single oral dose (0.1 mg/kg) or an IV dose (0.025 mg/kg) of tacrolimus, before and after 18 days of rifampin, 600 mg/d.…”

Section: Immunosuppressantsmentioning

confidence: 99%

Rifampin and Rifabutin Drug Interactions

Finch¹,

Chrisman²,

Baciewicz³

et al. 2002

Arch Intern Med

216

141

View full text Add to dashboard Cite

Rifampin is a potent inducer of cytochrome P-450 oxidative enzymes. A few examples of well-documented clinically significant interactions include interactions with warfarin, oral contraceptives, cyclosporine, glucocorticoids, ketoconazole or itraconazole, theophylline, quinidine sulfate, digitoxin or digoxin, verapamil hydrochloride, human immunodeficiency virus-related protease inhibitors, zidovudine, delavirdine mesylate, nifedipine, and midazolam. Recent reports have demonstrated clinically relevant interactions with numerous other drugs, such as buspirone hydrochloride, zolpidem tartrate, simvastatin, propafenone hydrochloride, tacrolimus, ondansetron hydrochloride, and opiates. Rifabutin reduces serum concentrations of antiretroviral agents, but less so than rifampin. To avoid a reduced therapeutic response, therapeutic failure, or toxic reactions when rifampin is added to or discontinued from medication regimens, clinicians need to be cognizant of these interactions. Enhanced knowledge of known interactions will continue to develop, including research on the induction of specific cytochrome P-450 isoenzymes and on the importance of the P-glycoprotein transport system. New rifampin and rifabutin interactions will be discovered with further investigations.

show abstract

Effects of Rifampin on Tacrolimus Pharmacokinetics in Healthy Volunteers

Cited by 129 publications

References 21 publications

Mycobacterium Tuberculosis Infection Incidence in Hospitalized Renal Transplant Patients in the United States, 1998–2000

Mycobacterium Tuberculosis Infection Incidence in Hospitalized Renal Transplant Patients in the United States, 1998–2000

Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal Extraction

Rifampin and Rifabutin Drug Interactions

Contact Info

Product

Resources

About